Abbott
ABBOTINDIA NSE
Abbott
HealthcareNSE: ABBOTINDIA BSE: 500488 Pharmaceuticals
Key Fundamentals
MidcapPharmaceuticalsHealthcareMarket Cap
₹53,538 Cr
Volatility
Low Risk
P/E Ratio
33.62
EBITDA
₹2,180 Cr
Return on Equity
32.51%
Debt to Equity
0.04
Book Value
₹2,246.68
EPS
₹583.05
52W High
₹31,495
52W Low
₹25,150
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
- Company has been maintaining a healthy dividend payout of 77.9%
Weaknesses
2- Stock is trading at 11.4 times its book value
- The company has delivered a poor sales growth of 9.96% over past five years.
Growth Rate
Revenue Growth
7.97% lower than
3Y
Net Income Growth
9.73% lower than
3Y
Cash Flow Change
30.38% higher than
3Y
ROE
-2.69% lower than
3Y
ROCE
-0.52% higher than
3Y
EBITDA Margin (Avg.)
2.51% lower than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 2d agoAI opinion · based on fundamentals
Risk medium
Abbott India Ltd is a debt-free healthcare company with a market cap of ₹53,538 Cr, trading at a PE of 33.3x and a price-to-book of 11.25x. The company has delivered consistent ROE of ~34-35% over the last 3-5 years and maintains a high dividend payout of 77.9%, but its stock has declined 18% over the past year and revenue growth has remained in single digits at 6% TTM.
Bull Case 7
- Company is virtually debt-free, providing strong balance sheet resilience and financial flexibility in an uncertain macro environment
- Consistently high return on equity at 34-35% over 3 and 5 years, well above the industry average, indicating efficient capital allocation
- Compounded profit growth of 17-18% over 3 and 5 years outpaces sales growth, reflecting improving operating leverage and margin expansion
- Healthy dividend payout ratio of 77.9% combined with a dividend yield of 2.6%, attractive for income-oriented investors in the pharma space
- Long-term compounded sales CAGR of 10% over 10 years and profit CAGR of 20% over 10 years demonstrate a durable growth franchise
- TTM profit growth of 11% continues to exceed TTM sales growth of 6%, suggesting ongoing cost discipline and margin improvement
- 10-year stock CAGR of 19% reflects sustained long-term wealth creation despite recent underperformance
Bear Case 7
- Stock is trading at 11.25x book value, a steep premium that leaves limited margin of safety if earnings growth slows
- Stock has declined 18% over the past 1 year, significantly underperforming the broader market and indicating negative sentiment
- Compounded sales growth has decelerated to just 6% TTM from 10% over 5 years, raising concerns about revenue momentum
- 3-year stock CAGR of only 3% and 5-year CAGR of 4% suggest the market has largely de-rated the stock over the medium term
- PE ratio of 33.3x is elevated for a company delivering only single-digit topline growth of 6% TTM, implying a high PEG ratio
- 5-year compounded sales growth of ~10% is modest for a company commanding a premium valuation in the healthcare sector
- Being an MNC subsidiary, Abbott India's strategic decisions including product launches, capital allocation, and dividend policy are driven by the parent, limiting minority shareholder influence
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 2h ago Neutral 1
- Company Secretary resignation accepted Sep 7
Abbott India accepted resignation of Sangeeta Shetty as Company Secretary and Compliance Officer, effective October 28, 2026. This is a routine corporate governance filing with no operational impact.
TL;DR: Limited news flow for Abbott India this period, with only a routine Company Secretary resignation disclosure. No material headwinds or positive catalysts emerged. The absence of negative news is modestly reassuring, but investors should watch for upcoming quarterly results and any regulatory developments in the healthcare sector for directional cues.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Expenses | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 |
| Operating Profit | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 |
| OPM % | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% |
| Other Income | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 |
| Depreciation | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 |
| PBT | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% |
| Net Profit | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| EPS in Rs | 137 | 147 | 146 | 135 | 154 | 169 | 170 | 173 | 172 | 195 | 177 | 186 | 202 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,919 | 5,349 | 5,849 | 6,409 | 6,929 | 7,004 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 5,037 | 5,035 |
| Operating Profit | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,088 | 1,206 | 1,453 | 1,695 | 1,892 | 1,969 |
| OPM % | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% | 28% |
| Other Income | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 77 | 154 | 248 | 275 | 288 | 291 |
| Interest | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 25 | 25 |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 76 | 76 |
| PBT | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,079 | 2,158 |
| Tax % | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | 25% | — |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,552 | 1,615 |
| EPS in Rs | 108 | 120 | 130 | 189 | 212 | 279 | 325 | 376 | 447 | 565 | 666 | 730 | 760 |
| Div. Payout % | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% | 90% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 4,753 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 172 |
| Other Liabilities | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,556 |
| Total Liabilities | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
| Fixed Assets | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 331 |
| CWIP | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 6,165 |
| Total Assets | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 6,502 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 | 1,319 |
| Investing | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 | -371 |
| Financing | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 | -1,066 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 | -118 |
| Free Cash Flow | 199 | 226 | 287 | 180 | 504 | 611 | 704 | 904 | 860 | 1,165 | 960 | 1,307 |
| CFO/OP | 106 | 109 | 117 | 68 | 125 | 113 | 104 | 114 | 102 | 111 | 86 | 98 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 | 19 |
| Inventory Days | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 | 94 |
| Days Payable | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 | 109 |
| Cash Conversion Cycle | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 | 3 |
| Working Capital Days | 30 | 32 | 21 | 63 | 22 | 10 | 4 | -7 | -8 | -14 | 99 | 2 |
| ROCE % | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% | 45% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Abbott insights
61 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Board Meeting Outcome for Outcome Of Board Meeting
5h - FY26 audited results approved; final dividend Rs525 and special dividend Rs131 per share, record date July 24. 5h - FY26 audited results approved; final dividend Rs525 and special dividend Rs131 per share, record date July 24.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil. 30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil.
3
Board Meeting Intimation for Considering Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026, Along With The Audit Report Of The Statutory Auditors Thereon And To Recommend Final Dividend For The Financial Year Ended March 31, 2026.
30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend. 30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend.
4
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil. 30 Apr - Abbott India says it was not a large corporate as of March 31, 2026; outstanding borrowing nil.
5
Board Meeting Intimation for Considering Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026, Along With The Audit Report Of The Statutory Auditors Thereon And To Recommend Final Dividend For The Financial Year Ended March 31, 2026.
30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend. 30 Apr - Board meets May 11, 2026 to approve FY26 audited results, financial statements, and final dividend.
1
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 7 Sept 2026
General_Announcements
Frequently Asked Questions about Abbott
What does Abbott India Ltd do?
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Where is Abbott India Ltd (ABBOTINDIA) listed?
Abbott India Ltd trades as ABBOTINDIA on the NSE and under code 500488 on the BSE.
Which sector does Abbott India Ltd belong to?
Abbott India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Abbott India Ltd?
Abbott India Ltd has a market capitalisation of ₹53,538 Cr, which places it in the Large Cap band.
What is the PE ratio of Abbott India Ltd?
Abbott India Ltd trades at a PE ratio of 33.62, on earnings per share of ₹583.05, against a book value of ₹2,246.68 per share.
What is the 52-week high and low of Abbott India Ltd?
Over the last 52 weeks Abbott India Ltd has traded between ₹25,150 and ₹31,495.
Does Abbott India Ltd pay dividends?
Abbott India Ltd has a dividend yield of 2.60%.
What is the Return on Equity (ROE) of Abbott India Ltd?
Abbott India Ltd reported a return on equity of 32.51%. Its debt-to-equity ratio is 0.04.
Company Information
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
Website abbott.co.in
CEO Mr. Kartik Rajendran
Employees 3,659
Listed 2010-01-08
Face Value ₹ 10
Issued Size 2,12,49,302
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ABBOTINDIA.md for Abbott India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.